[HTML][HTML] Pharmacogenetics of complement factor H Y402H polymorphism and treatment of neovascular AMD with anti-VEGF agents: a meta-analysis

G Chen, R Tzekov, W Li, F Jiang, S Mao, Y Tong - Scientific reports, 2015 - nature.com
G Chen, R Tzekov, W Li, F Jiang, S Mao, Y Tong
Scientific reports, 2015nature.com
The purpose of this study is to investigate whether the Y402H polymorphism (rs1061170, a T-
to-C transition at amino acid position 402) in the complement factor H (CFH) gene have a
pharmacogenetics effect on the anti-vascular endothelial growth factor (VEGF) treatment for
neovascular age-related macular degeneration (AMD). We performed a meta-analysis using
databases including PubMed and EMBASE to find relevant studies. 13 published
association studies were selected for this meta-analysis, including 2704 patients. For the …
Abstract
The purpose of this study is to investigate whether the Y402H polymorphism (rs1061170, a T-to-C transition at amino acid position 402) in the complement factor H (CFH) gene have a pharmacogenetics effect on the anti-vascular endothelial growth factor (VEGF) treatment for neovascular age-related macular degeneration (AMD). We performed a meta-analysis using databases including PubMed and EMBASE to find relevant studies. 13 published association studies were selected for this meta-analysis, including 2704 patients. For the CFH Y402H polymorphism, anti-VEGF treatment was much less effective in AMD patients with the CFH CC genotype (CC versus TT: odds ratio (OR) = 55, 95% confidence interval (CI), 0.31 to 0.95, P = 0.03; CC versus CT: OR = 0.60, 95% CI, 0.40 to 0.91, P = 0.02; and CC versus CT + TT: OR = 0.59, 95% CI, 0.38 to 0.90, P = 0.02, respectively). In subgroup analysis, CFH Y402H polymorphism was more likely to be a predictor of response for Caucasians (CC versus CT+TT: OR = 0.63, 95% CI, 0.42 to 0.95, P = 0.03). In conclusion, pharmacogenetics of CFH Y402H polymorphism may play a role in response to anti-VEGF treatment for neovascular AMD, especially for Caucasians.
nature.com